Tredje AP fonden Holds Holding in Illumina, Inc. (ILMN)

Tredje AP fonden Holds Holding in Illumina, Inc. (ILMN)

Tredje AP fonden continued to hold its position in shares of Illumina, Inc. (NASDAQ:ILMN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,656 shares of the life sciences company’s stock at the end of the first quarter. Tredje AP fonden’s holdings in Illumina were worth $11,033,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Baillie Gifford & Co. boosted its position in shares of Illumina by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 18,766,712 shares of the life sciences company’s stock worth $2,402,890,000 after buying an additional 178,559 shares in the last quarter. Edgewood Management LLC boosted its position in shares of Illumina by 33.6% in the fourth quarter. Edgewood Management LLC now owns 6,639,776 shares of the life sciences company’s stock worth $850,157,000 after buying an additional 1,671,293 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Illumina by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,632,576 shares of the life sciences company’s stock worth $841,554,000 after buying an additional 140,411 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Illumina during the fourth quarter worth about $140,899,000. 92.79% of the stock is currently owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ ILMN) traded up 1.94% on Friday, hitting $184.15. 573,800 shares of the company were exchanged. The stock has a 50 day moving average price of $179.78 and a 200 day moving average price of $159.27. Illumina, Inc. has a one year low of $119.37 and a one year high of $189.48. The firm has a market cap of $26.89 billion, a price-to-earnings ratio of 37.27 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The firm had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. During the same period last year, the company earned $0.71 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post $3.63 EPS for the current fiscal year.

Several brokerages have commented on ILMN. BTIG Research restated a “hold” rating on shares of Illumina in a research note on Sunday, March 19th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target on the stock in a research note on Tuesday, April 4th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 price target on the stock. in a research note on Tuesday, April 11th. Bank of America Corp raised their price target on shares of Illumina from $175.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, April 11th. Finally, Leerink Swann raised their price target on shares of Illumina from $134.00 to $138.00 and gave the company a “market perform” rating in a research note on Thursday, February 9th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $165.02.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the firm’s stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $163.56, for a total value of $98,136.00. Following the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at $2,791,151.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total value of $3,682,800.00. Following the completion of the transaction, the director now directly owns 539,176 shares in the company, valued at $99,283,868.64. The disclosure for this sale can be found here. Insiders sold a total of 51,346 shares of company stock valued at $9,242,907 over the last quarter. 1.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ILMN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Related posts

Leave a Comment